Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Sphingosine 1-phosphate receptor 1

7

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Investigational

3

Other

2

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

2

Phase III

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

2020

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Crohn's disease

4

Ulcerative colitis

4

Cutaneous lupus erythematosus

2

Multiple sclerosis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kyorin Pharmaceutical

2

Receptos

2

GlaxoSmithKline

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

7

FDA UNII

7

PUBCHEM

7

EPA CompTox

5

NCI_THESAURUS

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

IMMUNOSUPPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

IMMUNOSUPPRESSANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Selective immunosuppressants

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

5

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Ozanimod

Z80293URPV

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2020

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sphingosine 1-phosphate receptor 1

Sphingosine 1-phosphate receptor 5

Conditions:

Ulcerative colitis

Multiple sclerosis

Crohn's disease

Ozanimod (previously known as RPC-1063) is a selective immune-inflammatory modulator of the G protein-coupled receptors sphingosine 1-phosphate 1 and 5, which are part of the sphingosine 1-phosphate (S1P) receptor family. Treatment with S1P receptor ...

modulators interferes with S1P signaling and blocks the response of lymphocytes (a type of white blood cell) to exit signals from the lymph nodes, sequestering them within the nodes. The result is a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation. Ozanimod is currently in phase III clinical trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis, and also in phase II clinical trials to determine whether it is effective in the treatment of Crohn's disease.

GSK-2018682

NJL503AIJA

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingosine 1-phosphate receptor 1

Mocravimod

X71GCJ0HLI

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingosine 1-phosphate receptor 1

Conditions:

Ulcerative colitis

Cutaneous lupus erythematosus

Crohn's disease

KYORIN Pharmaceutical has developed a new sphingosine 1-phosphate (S1P) receptor type 1 agonist, 2-amino-2-propanediol hydrochloride (KRP-203), for immunomodulation in autoimmune diseases and organ transplantation. This drug was in phase II clinical ...

trial for the treatment Ulcerative Colitis, but this study was terminated. In addition, it has been investigated for the treatment of Cutaneous Lupus Erythematosus and Crohn's Disease, these phases II clinical trial studies were successfully completed.

SPHINGOSINE 1-PHOSPHATE

YVE187NJ1U

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sphingosine 1-phosphate receptor 1

Sphingosine 1-phosphate receptor 2

Sphingosine 1-phosphate receptor 3

Sphingosine 1-phosphate receptor 4

Sphingosine 1-phosphate receptor 5

FINGOLIMOD PHOSPHATE ESTER, (S)-

92YDM6122J

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sphingosine 1-phosphate receptor 3

Sphingosine 1-phosphate receptor 4

Sphingosine 1-phosphate receptor 1

Sphingosine 1-phosphate receptor 5

Ozanimod hydrochloride

3UPR33JAAM

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2020

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Sphingosine 1-phosphate receptor 1

Sphingosine 1-phosphate receptor 5

Conditions:

Ulcerative colitis

Multiple sclerosis

Crohn's disease

Ozanimod (previously known as RPC-1063) is a selective immune-inflammatory modulator of the G protein-coupled receptors sphingosine 1-phosphate 1 and 5, which are part of the sphingosine 1-phosphate (S1P) receptor family. Treatment with S1P receptor ...

modulators interferes with S1P signaling and blocks the response of lymphocytes (a type of white blood cell) to exit signals from the lymph nodes, sequestering them within the nodes. The result is a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation. Ozanimod is currently in phase III clinical trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis, and also in phase II clinical trials to determine whether it is effective in the treatment of Crohn's disease.

Mocravimod Hydrochloride

3YH0N35CE3

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sphingosine 1-phosphate receptor 1

Conditions:

Ulcerative colitis

Cutaneous lupus erythematosus

Crohn's disease

KYORIN Pharmaceutical has developed a new sphingosine 1-phosphate (S1P) receptor type 1 agonist, 2-amino-2-propanediol hydrochloride (KRP-203), for immunomodulation in autoimmune diseases and organ transplantation. This drug was in phase II clinical ...

trial for the treatment Ulcerative Colitis, but this study was terminated. In addition, it has been investigated for the treatment of Cutaneous Lupus Erythematosus and Crohn's Disease, these phases II clinical trial studies were successfully completed.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1